BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24183886)

  • 1. Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment.
    Acosta FJ; Ramallo-Fariña Y; Siris SG
    Compr Psychiatry; 2014 Jan; 55(1):33-9. PubMed ID: 24183886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
    Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
    Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
    Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.
    Novick D; Haro JM; Suarez D; Perez V; Dittmann RW; Haddad PM
    Psychiatry Res; 2010 Apr; 176(2-3):109-13. PubMed ID: 20185182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia.
    Brain C; Sameby B; Allerby K; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):215-22. PubMed ID: 24359935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).
    Acosta FJ; Ramallo-Fariña Y; Bosch E; Mayans T; Rodríguez CJ; Caravaca A
    Schizophr Res; 2013 May; 146(1-3):196-200. PubMed ID: 23474024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
    Lang K; Federico V; Muser E; Menzin J; Menzin J
    J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.
    Bressington D; Mui J; Gray R
    Int J Ment Health Nurs; 2013 Feb; 22(1):35-46. PubMed ID: 22738372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.
    Byerly M; Fisher R; Whatley K; Holland R; Varghese F; Carmody T; Magouirk B; Rush AJ
    Psychiatry Res; 2005 Feb; 133(2-3):129-33. PubMed ID: 15740989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
    Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J
    Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment adherence with antipsychotic medications in bipolar disorder.
    Sajatovic M; Valenstein M; Blow FC; Ganoczy D; Ignacio RV
    Bipolar Disord; 2006 Jun; 8(3):232-41. PubMed ID: 16696824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study.
    Misdrahi D; Tessier A; Husky M; Lange AC; Vrijens B; Llorca PM; Baylé FJ
    Schizophr Res; 2018 Mar; 193():114-118. PubMed ID: 28663027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients.
    Hashimoto Y; Uno J; Miwa T; Kurihara M; Tanifuji H; Tensho M
    Psychiatry Clin Neurosci; 2012 Aug; 66(5):405-10. PubMed ID: 22834658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.